Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.68 |
| ▸ | MET | P08581 | 4/20 | 0.68 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039383 | 0.89 | MAPK9 (0.66) | ALKMETGLO1FLT3MAPK9 | |
| SCHEMBL1038389 | 0.88 | SYK (0.69) | ALKMETGLO1EGFRSYK | |
| SCHEMBL1459616 | 0.85 | EGFR (0.56) | ALKMETGLO1MAPK9MAPK10 | |
| SCHEMBL600894 | 0.85 | GLO1 (0.56) | ALKMETGLO1EGFRLRRK2 | |
| SCHEMBL600864 | 0.85 | GLO1 (0.58) | ALKMETGLO1MAPK9MAPK10 | |
| SCHEMBL1460438 | 0.83 | EGFR (0.62) | ALKMETEGFRLRRK2 | |
| SCHEMBL10074552 | 0.80 | GLO1 (0.55) | ALKMETGLO1EGFRLRRK2 | |
| SCHEMBL20752146 | 0.80 | LRRK2 (0.65) | MAPK9MAPK10SYKLRRK2 | |
| SCHEMBL2121651 | 0.80 | ALK (0.59) | ALKMETGLO1FLT3EGFR | |
| SCHEMBL541915 | 0.79 | ALK (0.69) | ALKMETGLO1FLT3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | ALK 846/4885MET 4613/4885GLO1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.